These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 18061949)

  • 21. A comparison of morphologic features, flow cytometry, TCR-Vbeta analysis, and TCR-PCR in qualitative and quantitative assessment of peripheral blood involvement by Sézary syndrome.
    Morice WG; Katzmann JA; Pittelkow MR; el-Azhary RA; Gibson LE; Hanson CA
    Am J Clin Pathol; 2006 Mar; 125(3):364-74. PubMed ID: 16613339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of change in clinical status and change in the percentage of the CD4+CD26- lymphocyte population in patients with Sézary syndrome.
    Introcaso CE; Hess SD; Kamoun M; Ubriani R; Gelfand JM; Rook AH
    J Am Acad Dermatol; 2005 Sep; 53(3):428-34. PubMed ID: 16112348
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression and function of the natural cytotoxicity receptor NKp46 on circulating malignant CD4+ T lymphocytes of Sézary syndrome patients.
    Bensussan A; Remtoula N; Sivori S; Bagot M; Moretta A; Marie-Cardine A
    J Invest Dermatol; 2011 Apr; 131(4):969-76. PubMed ID: 21191411
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Epidermotropic T cell lymphomas as models for tumor progression].
    Bagot M; Bensussan A
    Med Sci (Paris); 2006 Feb; 22(2):192-6. PubMed ID: 16457762
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of KIR2D receptors on peripheral blood lymphocytes from liver graft recipients.
    López-Alvarez MR; Gómez-Mateo J; Ruiz-Merino G; Campillo JA; Miras M; García-Alonso AM; Sánchez-Bueno F; Parrilla P; Alvarez-López MR; Minguela A
    Transpl Immunol; 2006 Dec; 17(1):51-4. PubMed ID: 17157216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Membrane expression of NK receptors CD160 and CD158k contributes to delineate a unique CD4+ T-lymphocyte subset in normal and mycosis fungoides skin.
    Sako N; Schiavon V; Bounfour T; Dessirier V; Ortonne N; Olive D; Ram-Wolff C; Michel L; Sicard H; Marie-Cardine A; Bagot M; Bensussan A; Schmitt C
    Cytometry A; 2014 Oct; 85(10):869-82. PubMed ID: 25044837
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Polymorphic expression of CD158k/p140/KIR3DL2 in Sézary patients.
    Musette P; Michel L; Jean-Louis F; Bagot M; Bensussan A
    Blood; 2003 Feb; 101(3):1203. PubMed ID: 12529298
    [No Abstract]   [Full Text] [Related]  

  • 28. Primary Sézary syndrome commonly shows low-grade cytologic atypia and an absence of epidermotropism.
    Diwan AH; Prieto VG; Herling M; Duvic M; Jone D
    Am J Clin Pathol; 2005 Apr; 123(4):510-5. PubMed ID: 15743738
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The usefulness of CD26 in flow cytometric analysis of peripheral blood in Sézary syndrome.
    Kelemen K; Guitart J; Kuzel TM; Goolsby CL; Peterson LC
    Am J Clin Pathol; 2008 Jan; 129(1):146-56. PubMed ID: 18089499
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blood flow cytometry in Sézary syndrome: new insights on prognostic relevance and immunophenotypic changes during follow-up.
    Novelli M; Fava P; Sarda C; Ponti R; Osella-Abate S; Savoia P; Bergallo M; Lisa F; Fierro MT; Quaglino P
    Am J Clin Pathol; 2015 Jan; 143(1):57-69. PubMed ID: 25511143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunophenotypic stability of Sézary cells by flow cytometry: usefulness of flow cytometry in assessing response to and guiding alemtuzumab therapy.
    Vaughan J; Harrington AM; Hari PN; Kroft SH; Olteanu H
    Am J Clin Pathol; 2012 Mar; 137(3):403-11. PubMed ID: 22338052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytologic evaluation of lymphadenopathy associated with mycosis fungoides and Sezary syndrome: role of immunophenotypic and molecular ancillary studies.
    Pai RK; Mullins FM; Kim YH; Kong CS
    Cancer; 2008 Oct; 114(5):323-32. PubMed ID: 18798522
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Engagement of ILT2/CD85j in Sézary syndrome cells inhibits their CD3/TCR signaling.
    Nikolova M; Musette P; Bagot M; Boumsell L; Bensussan A
    Blood; 2002 Aug; 100(3):1019-25. PubMed ID: 12130517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunophenotypic analysis of peripheral T-cell neoplasms. A multiparameter flow cytometric approach.
    Jamal S; Picker LJ; Aquino DB; McKenna RW; Dawson DB; Kroft SH
    Am J Clin Pathol; 2001 Oct; 116(4):512-26. PubMed ID: 11601136
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peripheral blood findings in erythrodermic patients: importance for the differential diagnosis of Sézary syndrome.
    Nagler AR; Samimi S; Schaffer A; Vittorio CC; Kim EJ; Rook AH
    J Am Acad Dermatol; 2012 Mar; 66(3):503-8. PubMed ID: 22005074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitative flow cytometric identification of aberrant T cell clusters in erythrodermic cutaneous T cell lymphoma. Implications for staging and prognosis.
    Horna P; Deaver DM; Qin D; Moscinski LC; Sotomayor EM; Glass LF; Sokol L
    J Clin Pathol; 2014 May; 67(5):431-6. PubMed ID: 24319102
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Flow cytometry for the diagnosis of mycosis fungoides.
    Meyerson HJ
    G Ital Dermatol Venereol; 2008 Feb; 143(1):21-41. PubMed ID: 18833049
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Flow cytometric assessment of TCR-Vbeta expression in the evaluation of peripheral blood involvement by T-cell lymphoproliferative disorders: a comparison with conventional T-cell immunophenotyping and molecular genetic techniques.
    Morice WG; Kimlinger T; Katzmann JA; Lust JA; Heimgartner PJ; Halling KC; Hanson CA
    Am J Clin Pathol; 2004 Mar; 121(3):373-83. PubMed ID: 15023042
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Revisiting the initial diagnosis and blood staging of mycosis fungoides and Sézary syndrome with the KIR3DL2 marker.
    Roelens M; de Masson A; Ram-Wolff C; Maki G; Cayuela JM; Marie-Cardine A; Bensussan A; Toubert A; Bagot M; Moins-Teisserenc H
    Br J Dermatol; 2020 Jun; 182(6):1415-1422. PubMed ID: 31487384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Circulating natural killer lymphocytes are potential cytotoxic effectors against autologous malignant cells in sezary syndrome patients.
    Bouaziz JD; Ortonne N; Giustiniani J; Schiavon V; Huet D; Bagot M; Bensussan A
    J Invest Dermatol; 2005 Dec; 125(6):1273-8. PubMed ID: 16354199
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.